Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Netscientific associate Vortex Biosciences makes first commercial sale

VTX-1 is a fully automated benchtop system for collecting intact Circulating Tumour Cells (CTCs) for analysis
picture of blood
VTX-1 is a fully automated benchtop system for collecting Circulating Tumour Cells

Vortex BioSciences, a portfolio company of AIM-listed IP firm NetScientific PLC(LON:NSCI), has made the first direct commercial sale of its VTX-1 Liquid Biopsy System.

VTX-1 is a fully automated benchtop system for collecting intact Circulating Tumour Cells (CTCs) for analysis.

READ: NetScientific’s Glycotest subsidiary allowed Chinese patent for liver cancer blood test

The process traps unlabelled CTCs in microscale vortices from whole blood, allowing researchers to better understand cancer progression.

Francois Martelet, Vortex BioSciences’s chairman and NetScientific’s chief executive, said it was an important step towards commercialising VTX.

The system combines industry-leading purity and high CTC capture rates of between 65%-75%, which we believe can give researchers the opportunity to open new windows into our understanding of cancer. 

READ: NetScientific investee company's technology showcased in prestigious academic journal

Gene Walther, Vortex’s chief executive, added: "The reaction to the VTX-1 throughout the marketplace has been unbelievably positive, confirming both the tremendous potential CTCs offer and the unique value of the VTX-1."

View full NSCI profile View Profile

Netscientific PLC Timeline

Related Articles

picture of genes
November 29 2017
Among those cited as using Silence’s tech is US firm Alnylam, valued at US$12.7bn.
hepatitisC.jpg
July 27 2017
Regulatory sign-off will fire the starting pistol on the commercial launch in Europe
Cancer highlighted
July 10 2017
The collaboration will see PDS Biotechnology Corp and a subsidiary of Merck & Co Inc embark on a new clinical trial collaboration for metastatic head and neck cancer

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use